Olink Holding AB (publ)

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the All In Proteomics Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After this video's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automatic message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to end the conference over to your speaker host today, John Medina, Vice President of Investor Relations and Capital Markets. Please go ahead, sir.

Thanks, Livia, and good morning, everyone. Thank you all for participating in today's conference call. On the call from O-Link, we have John Hymer, Chief Executive Officer, Carl Raymond, Chief Commercial Officer, and Oscar Hjelm, Chief Financial Officer. Earlier today, O-Link released financial results for the fourth quarter ended December 31st, 2022, and a copy of the press release and an updated corporate presentation are available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the U.S. federal securities laws, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with OLINC's business, please refer to the risk factors section on Form 20F, Commission File Number 001-40277, filed with the U.S. Securities and Exchange Commission on March 17, 2022, and in our other filings with the SEC. We urge you to consider these factors and you should be aware that these statements should be considered estimates only and are not a guarantee of future performance. Also, in our remarks or responses to questions, management may mention some non-IFRS financial measures. Reconciliations of adjusted gross profit and EBITDA, constant currency revenue growth, and certain other non-IFRS financial measures to the most directly comparable IFRS measures are available in the recent earnings press release available on the company's website. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, February 21, 2023. O-Link disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise, except as required by law. And with that, I'll turn the call over to John. John?

Thank you, Jan, and good morning, everyone. And thanks for joining O-Link's fourth quarter 2022 earnings call. I'll begin with a review of O-Link's 2022 accomplishments, including recent operational, financial, and strategic milestones. I'll then turn the call over to Carl for details on our very strong commercial results and guidance. And then Oskar will discuss the company's financial performance. Q4 was another strong quarter and 2022 was another strong year for Olink. Our performance would not be possible without the enormous talent and drive of the entire organization. Olink met or exceeded every major corporate goal and put even more distance between us and competitors. Through science and customer-based market development, product design, and industry-leading execution, Olink has become the leader of the modern proteomics field, creating new insights at unprecedented scale across the entire research and development continuum. Over time, we expect Olink will enable proteomics to define a new approach to treating disease, providing new options for patients and all healthcare stakeholders. Proteomics is quickly becoming the most relevant omic for researchers and drug developers worldwide. In the fourth quarter, we delivered revenue of 57.9 million, representing 33% growth over the fourth quarter of 2021. While full year 2022 revenues was 139.8 million, a 47% increase compared to full year 2021. Once again, the quarter was highlighted by strong growth from Explore kits and kits revenue overall, demonstrating strong progress in our product mix goals. Other quarterly highlights included profitability, another record number of Explore externalizations, continued strong performance in the low and mid-plex markets by Signature Q100 and Target. We continue to see an expansion of proteomic workflows within customer accounts throughout the entire O-Link portfolio. This includes Explore users adopting the Signature and Target platforms as their work demands, as well as low- to mid-plex user moving towards high-plex projects. As we showcased on our Investor Day last November, Q4 was not simply about exemplary financial performance, but also about innovation. We continue to make progress in expanding the number of validated PEA assays, and by the end of 2022, we had a library of more than 5,000 carefully validated biomarker targets, surpassing an important internal R&D milestone to our goal of increasing throughput and simplifying workflows with the Olink platform. Also, in Q4, we launched Olink Insight, an open access platform for the global research community and Olink customers to share data and insights that will accelerate the value created by proteomics. We also launched Olink Flex. a made-to-order product that allows customers to create small protein panels from our library, while offering both relative and absolute quantification. After achieving the significant milestone of 1,000 published research studies in November, the number of PEA-based publications continued to increase, with the total now reaching more than 1,100, covering every major therapeutic category from research and discovery to the downstream clinical settings. One such publication from Professor Charlotte Tunison's group in Amsterdam provides a striking example of how large-scale biomarker discovery can be used to identify and validate protein signature using one scalable technology, in this case, PEA. In a study looking at different stages of AD, non-AD dementia, and healthy controls, Her team characterized CSS proteomes of people using 11 O-Link target 96 panels. The discovery phase identified over 100 proteins dysregulated in AD, and with data-driven modeling identified an eight-protein signature and a nine-protein signature, both discriminating AD from non-AD dementia with strong area under the curves. were then selected to construct a custom biomarker panel that showed high performance in a validation study with an AUC of 0.95 for AD versus controls and 0.79 for AD versus non-AD dementia. With the incredible challenge that Alzheimer's disease poses to human health, new advances such as this will be needed to improve outcomes. In summary, Olin continues to drive both the science and innovation of proteomics. delivering for customer and patients across life sciences and around the world. And we look forward to continuing this tradition in the months and years ahead. I'll now turn the call over to Karl to provide a few more details on the quarter. Karl?